Getagraph.com logo
NASDAQ Composite: ( -0.07%) 16 686
S&P 500
(0.12%) 5 303.27 points
Dow Jones
(0.34%) 40 004 points
Nasdaq
(-0.07%) 16 686 points
Oil
(-0.10%) $79.98
Gas
(1.41%) $2.66
Gold
(0.89%) $2 438.90
Silver
(4.02%) $32.52
Platinum
(0.93%) $1 100.10
USD/EUR
(-0.03%) $0.920
USD/NOK
(-0.06%) $10.67
USD/GBP
(0.01%) $0.787
USD/RUB
(0.09%) $91.05

Realtime updates for Neovacs SA [ALNEV.PA]

Exchange: EURONEXT Industry: Biotechnology
Last Updated17 May 2024 @ 11:25
25% discount on Stockinvest.us - Use code: Podcast

-9.24% 0.180

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 11:25):

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France...

Stats
Today's Volume 72 444.00
Average Volume 13 099.00
Market Cap 63 198.00
EPS 0 ( 2019-10-02 )
Last Dividend 0 ( N/A )
Next Dividend 0 ( N/A )
P/E -0.0100
ATR14 0.00600 (3.34%)

Neovacs SA Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Neovacs SA Financials

Annual 2023
Revenue: 533 412
Gross Profit: -6.75M (-1 266.26 %)
EPS: -0.00250
FY 2023
Revenue: 533 412
Gross Profit: -6.75M (-1 266.26 %)
EPS: -0.00250
FY 2022
Revenue: 1 112.00
Gross Profit: -3.43M (-308 866.37 %)
EPS: -117.60
FY 2021
Revenue: 22 595.00
Gross Profit: -462 306 (-2 046.05 %)
EPS: -7 841.13

Financial Reports:

No articles found.

Neovacs SA Options Data

Calls

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Puts

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Neovacs SA

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators